Commission Delegated Regulation (EU) 2020/1182 of 19 May 2020 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

Amendments to Regulation (EC) No 1272/2008

Article 1

Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Entry into force and application

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 1 March 2022. By way of derogation from the second paragraph of this Article, substances and mixtures may, before 1 March 2022 be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

ANNEXSupplementary provisions

ANNEX In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows: (1) the following entries are inserted: Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘007-030-00-3 nitric acid …% [C ≤ 70 %] 231-714-2 7697-37-2. Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A H272 H331 H314 GHS03 GHS06 GHS05 Dgr H272 H331 H314 EUH071 Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % B’ ‘014-048-00-5 silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) 206-991-8 409-21-2 308076-74-6 Carc. 1B H350i GHS08 Dgr H350i’       ‘014-049-00-0 trimethoxyvinylsilane; trimethoxy(vinyl)silane 220-449-8 2768-02-7 Skin Sens. 1B H317 GHS07 Wng H317’       ‘014-050-00-6 tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane 213-934-0 1067-53-4 Repr. 1B H360FD GHS08 Dgr H360FD’       ‘016-098-00-3 dimethyl disulphide 210-871-0 624-92-0 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410 GHS02 GHS06 GHS08 GHS09 Dgr H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410   inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/kg bw M = 1 M = 10’   ‘029-024-00-X granulated copper; [particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm] 231-159-6 7440-50-8 Aquatic Chronic 2 H411 GHS09 H411’       ‘029-025-00-5 bis( N -hydroxy- N -nitrosocyclohexylaminato- O , O ’)copper; bis( N -cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO] 239-703-4 312600-89-8 15627-09-5 Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H228 H302 H373 (liver) H318 H400 H410 GHS02 GHS07 GHS08 GHS05 GHS09 Dgr H228 H302 H373(liver) H318 H410   oral: ATE = 360 mg/kg bw M = 1 M = 1’   ‘050-031-00-9 dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2] 222-883-3 [1] 293-901-5 [2] 3648-18-8 [1] 91648-39-4 [2] Repr. 1B STOT RE 1 H360D H372 (immune system) GHS08 Dgr H360D H372 (immune system)’       ‘601-092-00-0 dibenzo[ def , p ]chrysene; dibenzo[ a , l ]pyrene 205-886-4 191-30-0 Carc. 1B Muta. 2 H350 H341 GHS08 Dgr H350 H341   Carc. 1B; H350: C ≥ 0,001 %’   ‘603-237-00-3 ipconazole (ISO); (1 RS ,2 SR ,5 RS ;1 RS ,2 SR ,5 SR )-2-(4-chlorobenzyl)-5-isopropyl-1-(1 H -1,2,4-triazol-1-ylmethyl)cyclopentanol - 125225-28-7 115850-69-6 115937-89-8 Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 H360D H302 H373 (eyes, skin, liver) H410 GHS08 GHS07 GHS09 Dgr H360D H302 H373 (eyes, skin, liver) H410   oral: ATE = 500 mg/kg bw M = 100’   ‘603-238-00-9 bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme 205-594-7 143-24-8 Repr. 1B H360FD GHS08 Dgr H360FD’       ‘603-239-00-4 paclobutrazol (ISO); (2 RS ,3 RS )-1-(4-chlorophenyl)-4,4-dimethyl-2-(1 H -1,2,4-triazol-1-yl)pentan-3-ol - 76738-62-0 Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H302 H319 H400 H410 GHS08 GHS07 GHS09 Wng H361d H332 H302 H319 H410   inhalation: ATE = 3,13 mg/L (dusts or mists) oral: ATE = 490 mg/kg bw M = 10 M = 10’   ‘603-240-00-X 2,2-bis(bromomethyl)propane-1,3-diol 221-967-7 3296-90-0 Carc. 1B Muta. 1B H350 H340 GHS08 Dgr H350 H340’       ‘603-241-00-5 geraniol; (2 E )-3,7-dimethylocta-2,6-dien-1-ol 203-377-1 106-24-1 Skin Sens. 1 H317 GHS07 Wng H317’       ‘605-041-00-3 2-(4- tert -butylbenzyl)propionaldehyde 201-289-8 80-54-6 Repr. 1B H360Fd GHS08 Dgr H360Fd’       ‘607-738-00-8 MCPA-thioethyl (ISO); S -ethyl (4-chloro-2-methylphenoxy)ethanethioate; S -ethyl 4-chloro- o -tolyloxythioacetate 246-831-4 25319-90-8 Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (liver) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (liver) H410   oral: ATE = 450 mg/kg bw M = 10 M = 10’   ‘607-740-00-9 diisooctyl phthalate 248-523-5 27554-26-3 Repr. 1B H360FD GHS08 Dgr H360FD’       ‘607-741-00-4 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5 H )-one; flupyradifurone - 951659-40-8 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (muscle) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (muscle) H410   oral: ATE = 500 mg/kg bw M = 10 M = 10’   ‘607-742-00-X thiencarbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate - 317815-83-1 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1000 M = 1000’   ‘607-743-00-5 L-(+)-lactic acid; (2 S )-2-hydroxypropanoic acid 201-196-2 79-33-4 Skin Corr. 1C Eye Dam. 1 H314 H318 GHS05 Dgr H314 EUH071’     ‘607-744-00-0 2-methoxyethyl acrylate 221-499-3 3121-61-7 Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 H226 H341 H360FD H331 H302 H314 H318 H317 GHS02 GHS05 GHS06 GHS08 Dgr H226 H341 H360FD H331 H302 H314 H317 EUH071 inhalation: ATE = 2,7 mg/L (vapours) oral: ATE = 404 mg/kg bw’   ‘607-745-00-6 glyoxylic acid …% 206-058-5 298-12-4 Eye Dam. 1 Skin Sens. 1B H318 H317 GHS05 GHS07 Dgr H318 H317     B’ ‘607-746-00-1 sodium N -(hydroxymethyl)glycinate; [formaldehyde released from sodium N -(hydroxymethyl)glycinate] 274-357-8 70161-44-3 Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H350 H341 H332 H302 H335 H315 H319 H317 GHS08 GHS07 Dgr H350 H341 H332 H302 H335 H315 H319 H317   inhalation: ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/kg bw 8 9’ ‘611-181-00-6 potassium (oxido- NNO -azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO] - 66603-10-9 Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 H228 H301 H373 (liver) H315 H318 H411 GHS02 GHS06 GHS08 GHS05 GHS09 Dgr H228 H301 H373 (liver) H315 H318 H411   oral: ATE = 136 mg/kg bw’   ‘612-294-00-3 mecetronium etilsulfate; N -ethyl- N , N -dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate; [MES] 221-106-5 3006-10-8 Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H314 H318 H400 H410 GHS05 GHS09 Dgr H314 H410 EUH071 M = 100 M = 1000’   ‘613-331-00-6 (2 RS )-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1 H -1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole - 1417782-03-6 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410   M = 1 M = 1’   ‘613-332-00-1 oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1 H -pyrazol-1-yl]ethanone - 1003318-67-9 Aquatic Chronic 1 H410 GHS09 Wng H410   M = 1’   ‘613-333-00-7 pyrithione zinc; ( T -4)-bis[1-(hydroxy-.kappa. O )pyridine-2(1 H )-thionato-.kappa. S ]zinc 236-671-3 13463-41-7 Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H301 H372 H318 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H360D H330 H301 H372 H318 H410   inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/kg bw M = 1000 M = 10’   ‘613-334-00-2 flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one 262-661-3 61213-25-0 Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360FD H302 H317 H400 H410 GHS08 GHS07 GHS09 Dgr H360FD H302 H317 H410   oral: ATE = 500 mg/kg bw M = 100 M = 100’   ‘613-335-00-8 4,5-dichloro-2-octyl-2 H -isothiazol-3-one; [DCOIT] 264-843-8 64359-81-5 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H314 H317 H410 EUH071 inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’   ‘613-336-00-3 2-methyl-1,2-benzothiazol-3(2 H )-one; [MBIT] - 2527-66-4 Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 H312 H301 H314 H318 H317 H400 H411 GHS06 GHS05 GHS09 Dgr H312 H301 H314 H317 H410 EUH071 dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1’   ‘616-228-00-4 3-(difluoromethyl)-1-methyl- N -(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad - 907204-31-3 Lact. Aquatic Acute 1 Aquatic Chronic 1 H362 H400 H410 GHS09 Wng H362 H410   M = 1 M = 1’   ‘616-230-00-5 N -(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] 213-103-2 924-42-5 Carc. 1B Muta. 1B STOT RE 1 H350 H340 H372 (peripheral nervous system) GHS08 Dgr H350 H340 H372 (peripheral nervous system)’       ‘616-231-00-0 5-fluoro-1,3-dimethyl- N -[2-(4-methylpentan-2-yl)phenyl]-1 H -pyrazole-4-carboxamide; 2'-[( RS )-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen - 494793-67-8 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410   M = 1 M = 1’   ‘616-232-00-6 iprovalicarb (ISO); isopropyl [(2 S )-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate - 140923-17-7 Carc. 2 H351 GHS08 Wng H351’       ‘616-233-00-1 silthiofam (ISO); N -allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide - 175217-20-6 STOT RE 2 Aquatic Chronic 2 H373 H411 GHS08 GHS09 Wng H373 H411’       ‘650-057-00-6 Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] 283-644-7 84696-25-3 Aquatic Chronic 3 H412   H412’       (2) the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively: Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘007-004-00-1 nitric acid …% [C > 70 %] 231-714-2 7697-37-2 Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A H272 H330 H314 GHS03 GHS06 GHS05 Dgr H272 H330 H314 EUH071 Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 % B’ ‘014-018-00-1 octamethylcyclotetrasiloxane; [D4] 209-136-7 556-67-2 Repr. 2 Aquatic Chronic 1 H361f *** H410 GHS08 GHS09 Wng H361f *** H410   M = 10’   ‘015-134-00-5 pirimiphos-methyl (ISO); O -[2-(diethylamino)-6-methylpyrimidin-4-yl] O , O -dimethyl phosphorothioate 249-528-5 29232-93-7 Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H372 (nervous system) H400 H410 GHS07 GHS08 GHS09 Dgr H302 H372 (nervous system) H410   oral: ATE = 1414 mg/kg bw M = 1000 M = 1000’   ‘015-181-00-1 phosphine 232-260-8 7803-51-2 Flam. Gas 1 Press. Gas Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1 H220 H330 H314 H400 GHS02 GHS04 GHS06 GHS05 GHS09 Dgr H220 H330 H314 H400   inhalation: ATE = 10 ppmV (gases) U’ ‘050-021-00-4 dichlorodioctylstannane 222-583-2 3542-36-7 Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3 H360D H330 H372 ** H412 GHS08 GHS06 Dgr H360D H330 H372 ** H412   Repr. 1B; H360 D: C ≥ 0,03 % inhalation: ATE = 0,098 mg/L (dusts or mists)’   ‘050-027-00-7 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE] 239-622-4 15571-58-1 Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H372 (immune system) H400 H410 GHS08 GHS09 Dgr H360D H372 (immune system) H410’       ‘082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 H360FD H362 H400 H410 GHS08 GHS09 Dgr H360FD H362 H410   Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10’   ‘603-014-00-0 2-butoxyethanol; ethylene glycol monobutyl ether 203-905-0 111-76-2 Acute Tox. 4* Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 H332 H302 H315 H319 GHS07 Wng H332 H302 H315 H319   oral: ATE = 1200 mg/kg bw’   ‘603-065-00-9 m -bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether 202-987-5 101-90-6 Carc. 1B Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 H350 H341 H311 H302 H315 H319 H317 H412 GHS08 GHS06 Dgr H350 H341 H311 H302 H315 H319 H317 H412   dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’   ‘607-177-00-9 tribenuron-methyl (ISO); methyl 2-[ N -(4-methoxy-6-methyl-1,3,5-triazin-2-yl)- N -methylcarbamoylsulfamoyl]benzoate 401-190-1 101200-48-0 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H373 H317 H400 H410 GHS08 GHS07 GHS09 Wng H373 H317 H410   M = 100 M = 100’   ‘607-256-00-8 azoxystrobin (ISO); methyl ( E )-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate - 131860-33-8 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H331 H400 H410 GHS06 GHS09 Dgr H331 H410   inhalation: ATE = 0,7 mg/L (dusts or mists) M = 10 M = 10’   ‘607-314-00-2 ethofumesate (ISO); ( RS )-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate 247-525-3 26225-79-6 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1 M = 1’   ‘609-041-00-4 2,4-dinitrophenol 200-087-7 51-28-5 Acute Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1 H331 H311 H300 H372 H400 GHS06 GHS08 GHS09 Dgr H331 H311 H300 H372 H400   dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’   ‘609-064-00-X mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione - 104206-82-8 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H373 (eyes, nervous system) H400 H410 GHS08 GHS09 Wng H361d H373 (eyes, nervous system) H410   M = 10 M = 10’   ‘613-112-00-5 octhilinone (ISO); 2-octyl-2 H -isothiazol-3-one; [OIT] 247-761-7 26530-20-1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H311 H301 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H311 H301 H314 H317 H410 EUH071 inhalation: ATE = 0,27 mg/L (dusts or mists) dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’   ‘613-115-00-1 hymexazol (ISO); 3-hydroxy-5-methylisoxazole 233-000-6 10004-44-1 Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 H361d H302 H318 H317 H411 GHS08 GHS07 GHS05 GHS09 Dgr H361d H302 H318 H317 H411   oral: ATE = 1600 mg/kg bw’   ‘613-125-00-6 hexythiazox (ISO); trans -5-(4-chlorophenyl)- N -cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide - 78587-05-0 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1 M = 1’   ‘613-202-00-4 pymetrozine (ISO); ( E )-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2 H )-one - 123312-89-0 Carc. 2 Repr. 2 Aquatic Chronic 1 H351 H361fd H410 GHS08 GHS09 Wng H351 H361fd H410   M = 1’   ‘613-259-00-5 imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1 R )- cis -chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1 R )- trans -chrysanthemate 428-790-6 72963-72-5 Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410 GHS08 GHS07 GHS09 Wng H351 H332 H302 H371 (nervous system; oral, inhalation) H410   inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/kg bw M = 10 M = 10’   ‘616-014-00-0 butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime 202-496-6 96-29-7 Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 GHS08 GHS06 GHS05 Dgr H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317   dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’   ‘617-006-00-X bis(α,α-dimethylbenzyl) peroxide 201-279-3 80-43-3 Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2 H242 H360D H315 H319 H411 GHS02 GHS08 GHS07 GHS09 Dgr H242 H360D H315 H319 H411’       (3) the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.